Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors

被引：0
|
作者：
Johnson, M. [1 ]
Galsky, M. [2 ]
Barve, M. [3 ]
Goel, S. [4 ]
Park, H. [5 ]
Du, B. [6 ]
Mu, S. [7 ]
Ramakrishnan, V. [8 ]
Wood, K. [9 ]
Wang, V. [10 ]
Lakhani, N. [11 ]
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA
[3] Mary Crowley Canc Res, Med Oncol, Dallas, TX USA
[4] Montefiore Med Ctr, Med Oncol, 111 E 210th St, Bronx, NY 10467 USA
[5] Washington Univ, Med Oncol, St Louis, MO USA
[6] Beigene USA Inc, Pharmacovigilance & Drug Safety, San Mateo, CA USA
[7] BeiGene USA Inc, Clin Pharmacol, Ft Lee, NJ USA
[8] BeiGene USA Inc, CDx & Biomarker Dev, San Mateo, CA USA
[9] BeiGene USA Inc, Clin Sci, San Mateo, CA USA
[10] BeiGene USA Inc, Biostat, San Mateo, CA USA
[11] START Midwest, Dev Therapeut, Grand Rapids, MI USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421P
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [31] A phase 1 dose-escalation study of safety, tolerability, and pharmacokinetics (PK) of ABBV-368 monotherapy and combination in patients (pts) with locally advanced or metastatic solid tumors
    Le Tourneau, Christophe
    Su, Wu-Chou
    Chung, Ki
    LoRusso, Patricia
    Lin, Chia-Chi
    Barlesi, Fabrice
    Shiah, Her-Shyong
    Angevin, Eric
    Spira, Alexander
    Patnaik, Amita
    Powderly, John
    Colevas, Dimitrios
    Chew, Helen
    Patel, Maulik
    Lambert, Stacie
    Li, Yan
    Da Costa, Daniel
    Blaney, Martha
    McDevitt, Michael
    Cassier, Philippe
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [32] A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab
    Moser, Justin C.
    Opyrchal, Mateusz
    Rivera, Ildefonso Rodriguez
    Curti, Brendan D.
    Puzanov, Igor
    Sosman, Jeffrey A.
    Bilen, Mehmet Asim
    Morris, Kristin
    Nirschl, Christopher J.
    Park, Saero
    Bruno, Marissa
    Windt, Paul
    Subramanian, Kulandayan K.
    Schonborn-Kellenberger, Oliver
    Chopra, Sameer
    Isaacs, Randi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Phase I study of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with metastatic/locally advanced solid unresectable tumours
    Siu, L. L.
    Mckean, M. A.
    Tolcher, A. W.
    Victor, A.
    Kitzing, T.
    Pierre, V.
    Gleicher, S.
    Holland, D. G.
    Richter, E.
    Naing, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S887 - S887
  • [34] Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors
    Shubham Pant
    Tomislav Dragovich
    Christopher Lieu
    Antonio Jimeno
    Madappa Kundranda
    David Menter
    Eskouhie Tchaparian
    Yuchih C. Chen
    Scott Kopetz
    Investigational New Drugs, 2023, 41 : 25 - 34
  • [35] Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors
    Pant, Shubham
    Dragovich, Tomislav
    Lieu, Christopher
    Jimeno, Antonio
    Kundranda, Madappa
    Menter, David
    Tchaparian, Eskouhie
    Chen, Yuchih C.
    Kopetz, Scott
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 25 - 34
  • [36] MULTICENTER, DOSE-ESCALATION STUDY OF THE INVESTIGATIONAL DRUG TAK-733, AN ORAL MEK INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: PRELIMINARY PHASE 1 RESULTS
    Adjei, A. A.
    LoRusso, P. M.
    Ribas, A.
    Sosman, J. A.
    Dy, G. K.
    Chmielowski, B.
    Lipman, P.
    Zhou, X.
    Gangolli, E.
    Bozon, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 158 - 158
  • [37] A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
    Jayesh Desai
    Peter Fong
    Victor Moreno
    Sophia Frentzas
    Tarek Meniawy
    Ben Markman
    Mark Voskoboynik
    Tahmina Rahman
    Nageshwar Budha
    John Wu
    Jin Marlow
    Silu Yang
    Emiliano Calvo
    Juan Martin-Liberal
    British Journal of Cancer, 2023, 128 : 1418 - 1428
  • [38] A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
    Desai, Jayesh
    Fong, Peter
    Moreno, Victor
    Frentzas, Sophia
    Meniawy, Tarek
    Markman, Ben
    Voskoboynik, Mark
    Rahman, Tahmina
    Budha, Nageshwar
    Wu, John
    Marlow, Jin
    Yang, Silu
    Calvo, Emiliano
    Martin-Liberal, Juan
    BRITISH JOURNAL OF CANCER, 2023, 128 (08) : 1418 - 1428
  • [39] Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors
    Chu, Quincy Siu-chung
    Bouganim, Nathaniel
    Fortier, Caroline
    Zaknoen, Sara
    Stille, John R.
    Kremer, Jill D.
    Yuen, Eunice
    Hui, Yu-Hua
    de la Pena, Amparo
    Lithio, Andrew
    Smith, Patricia S.
    Batist, Gerald
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1001 - 1010
  • [40] Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors
    Quincy Siu-chung Chu
    Nathaniel Bouganim
    Caroline Fortier
    Sara Zaknoen
    John R. Stille
    Jill D. Kremer
    Eunice Yuen
    Yu-Hua Hui
    Amparo de la Peña
    Andrew Lithio
    Patricia S. Smith
    Gerald Batist
    Investigational New Drugs, 2021, 39 : 1001 - 1010
12345